Usca Ria LLC reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 28.1% during the 3rd quarter, Holdings Channel reports. The firm owned 99,402 shares of the biopharmaceutical company’s stock after selling 38,915 shares during the quarter. Usca Ria LLC’s holdings in Gilead Sciences were worth $7,675,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Reilly Financial Advisors LLC raised its position in Gilead Sciences by 98.3% in the third quarter. Reilly Financial Advisors LLC now owns 1,420 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 704 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in Gilead Sciences in the second quarter valued at approximately $132,000. Brand Asset Management Group Inc. purchased a new stake in Gilead Sciences in the second quarter valued at approximately $139,000. TRUE Private Wealth Advisors purchased a new stake in Gilead Sciences in the third quarter valued at approximately $174,000. Finally, Truvestments Capital LLC purchased a new stake in Gilead Sciences in the third quarter valued at approximately $210,000. Institutional investors and hedge funds own 78.09% of the company’s stock.
Gilead Sciences stock opened at $71.18 on Wednesday. Gilead Sciences, Inc. has a twelve month low of $64.27 and a twelve month high of $89.54. The company has a debt-to-equity ratio of 1.36, a quick ratio of 3.39 and a current ratio of 3.47. The firm has a market cap of $90.02 billion, a PE ratio of 8.32, a P/E/G ratio of -2.69 and a beta of 1.01.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Gilead Sciences had a return on equity of 39.32% and a net margin of 7.12%. The business had revenue of $5.60 billion for the quarter, compared to analyst estimates of $5.44 billion. During the same quarter in the prior year, the company earned $2.27 earnings per share. Analysts predict that Gilead Sciences, Inc. will post 6.44 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 28th. Stockholders of record on Friday, December 14th will be given a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.20%. The ex-dividend date of this dividend is Thursday, December 13th. Gilead Sciences’s dividend payout ratio is currently 26.64%.
GILD has been the topic of a number of research analyst reports. BidaskClub raised Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, July 10th. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $86.00 target price on the stock in a research report on Wednesday, July 18th. Robert W. Baird lowered Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 target price on the stock. in a research report on Thursday, July 26th. Wells Fargo & Co boosted their target price on Gilead Sciences from $89.00 to $95.00 and gave the company an “outperform” rating in a research report on Thursday, July 26th. Finally, Morgan Stanley boosted their target price on Gilead Sciences from $81.00 to $85.00 and gave the company an “equal weight” rating in a research report on Thursday, July 26th. Thirteen investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and an average price target of $87.84.
In related news, Director John C. Martin sold 50,000 shares of the business’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $78.04, for a total transaction of $3,902,000.00. Following the completion of the transaction, the director now owns 3,067,762 shares in the company, valued at $239,408,146.48. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders have sold 150,000 shares of company stock worth $11,087,500 in the last ninety days. Corporate insiders own 1.16% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/11/07/usca-ria-llc-sells-38915-shares-of-gilead-sciences-inc-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Article: What is a Swap?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.